Core Scientific’s Q4 2025 results missed expectations and highlighted a familiar tension for markets: the difference between GAAP optics and operational reality. Revenue came in at $79.8 million, well below analyst projections in the ~$115.92 million to $124.5 million range, and adjusted EBITDA was negative at $(42.7) million, which helped drive a selloff in the stock. Investors weren’t impressed by headline earnings if the underlying business still isn’t generating cash.
The market reaction reflected that quality-of-earnings framing. Core Scientific fell 2.83% in the March 2, 2026 regular session and dropped another 1.62% after hours. That price action signals the market is underwriting the transition story cautiously and using cash-generation proxies as the main scorecard.
Why GAAP looked fine while operations didn’t
Core Scientific reported GAAP diluted EPS of $0.42, but that number was boosted by a $330.3 million non-cash fair value gain tied to revaluing warrant and contingent value right liabilities. This is exactly the kind of accounting move that can make earnings look healthy without improving the company’s ability to fund itself. When you strip that out, the operational picture is what adjusted EBITDA is telling you: negative profitability and no clear margin expansion in the quarter.
That is why analysts and market participants read the quarter as a quality-of-earnings issue. Positive GAAP EPS alongside negative adjusted EBITDA tends to trigger skepticism, because it suggests the earnings “engine” is accounting-driven rather than operationally repeatable. In a capital-intensive business, that distinction matters a lot—especially when investors are looking for predictable cash flow to support a strategic pivot.
The transition story is still ahead of the numbers
Management has been pushing a repositioning narrative away from legacy Bitcoin mining toward AI infrastructure and colocation services, pointing to an AI contract pipeline and partnerships. The Q4 print implies that whatever is in the pipeline has not yet translated into revenue at the scale investors expected, at least not enough to offset the quarter’s revenue decline and deliver operational leverage. Year on year, revenue was down about 15.9%, reinforcing that the old business is not providing a stable floor while the new business ramps.
So the company is in a classic “in-between” phase: operational metrics are under pressure while spending and effort are going into the new strategy. The market will keep asking one question until it gets a clean answer: does AI and colocation become recurring, contracted cash flow that can be forecast and banked? Until that shows up in the income statement and cash metrics, the stock is likely to trade on near-term operational performance rather than GAAP distortions from non-cash revaluations.
The path to restoring confidence is not about another quarter of accounting upside; it’s about execution. Core Scientific needs to convert its AI pipeline into sustained revenue and show a credible trajectory toward positive operational cash flow. If that happens, valuation can shift toward longer-duration confidence in the new business model; if it doesn’t, investors will continue treating the company as a transition story with a cash-flow gap.
